Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats
Purpose: Methamphetamine (METH) abuse is associated with hepatic dysfunction related comorbidities such as HIV, hepatitis C, and polysubstance abuse with acetaminophen-containing opioid formulations. We aimed to develop a bile duct ligation (BDL)-induced hepatic dysfunction model for studying both...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Canadian Society for Pharmaceutical Sciences
2019-07-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30471 |
id |
doaj-f7afe7f33588490594ed5cde539341a7 |
---|---|
record_format |
Article |
spelling |
doaj-f7afe7f33588490594ed5cde539341a72020-11-25T03:36:56ZengCanadian Society for Pharmaceutical SciencesJournal of Pharmacy & Pharmaceutical Sciences1482-18262019-07-0122110.18433/jpps30471Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in RatsMichael D Hambuchen0Michael D Berquist1Christy M Simecka2Mitchell R McGill3Melinda G Gunnell4Howard P Hendrickson5S Michael Owens6Department of Pharmaceutical Science and Research, Marshall University School of Pharmacy, Huntington, WV, USA. Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USADepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.Division of Laboratory Animal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.Department of Environmental and Occupational Health, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR , USA.Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.Department of Pharmaceutical, Social, and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA. Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Purpose: Methamphetamine (METH) abuse is associated with hepatic dysfunction related comorbidities such as HIV, hepatitis C, and polysubstance abuse with acetaminophen-containing opioid formulations. We aimed to develop a bile duct ligation (BDL)-induced hepatic dysfunction model for studying both METH and experimental treatments for METH abuse in this comorbidity. Methods: Sham or BDL surgery was performed in male Wistar rats on day 0. Liver function was measured throughout the study. On days 7 and 19, serum pharmacokinetics studies were performed with 1 mg/kg subcutaneous (sc) METH. On day 21, this dose was repeated to determine 2 h post-METH brain concentrations. METH-induced open field behaviors were measured every other day (days 12 - 16) with ascending sc doses (0.3 – 3 mg/kg). Results: BDL transiently increased alanine aminotransferase levels and altered liver structure, which resulted in significantly greater METH serum and brain exposure. In the BDL compared to sham group, there was a longer duration of METH-induced locomotor activity (after 1 and 3 mg/kg) and stereotypy (after 3 mg/kg). Conclusions: In rats, liver dysfunction reduced METH clearance, increased brain METH concentrations, and enhanced METH effects on locomotor activity in a dose dependent manner. In addition, this model could be further developed to simulate the associated hepatic dysfunction of key METH abuse comorbidities for preclinical testing of novel pharmacotherapies for effectiveness and/or toxicity in vulnerable populations. https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30471 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael D Hambuchen Michael D Berquist Christy M Simecka Mitchell R McGill Melinda G Gunnell Howard P Hendrickson S Michael Owens |
spellingShingle |
Michael D Hambuchen Michael D Berquist Christy M Simecka Mitchell R McGill Melinda G Gunnell Howard P Hendrickson S Michael Owens Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats Journal of Pharmacy & Pharmaceutical Sciences |
author_facet |
Michael D Hambuchen Michael D Berquist Christy M Simecka Mitchell R McGill Melinda G Gunnell Howard P Hendrickson S Michael Owens |
author_sort |
Michael D Hambuchen |
title |
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats |
title_short |
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats |
title_full |
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats |
title_fullStr |
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats |
title_full_unstemmed |
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats |
title_sort |
effect of bile duct ligation-induced liver dysfunction on methamphetamine pharmacokinetics and locomotor activity in rats |
publisher |
Canadian Society for Pharmaceutical Sciences |
series |
Journal of Pharmacy & Pharmaceutical Sciences |
issn |
1482-1826 |
publishDate |
2019-07-01 |
description |
Purpose: Methamphetamine (METH) abuse is associated with hepatic dysfunction related comorbidities such as HIV, hepatitis C, and polysubstance abuse with acetaminophen-containing opioid formulations. We aimed to develop a bile duct ligation (BDL)-induced hepatic dysfunction model for studying both METH and experimental treatments for METH abuse in this comorbidity. Methods: Sham or BDL surgery was performed in male Wistar rats on day 0. Liver function was measured throughout the study. On days 7 and 19, serum pharmacokinetics studies were performed with 1 mg/kg subcutaneous (sc) METH. On day 21, this dose was repeated to determine 2 h post-METH brain concentrations. METH-induced open field behaviors were measured every other day (days 12 - 16) with ascending sc doses (0.3 – 3 mg/kg). Results: BDL transiently increased alanine aminotransferase levels and altered liver structure, which resulted in significantly greater METH serum and brain exposure. In the BDL compared to sham group, there was a longer duration of METH-induced locomotor activity (after 1 and 3 mg/kg) and stereotypy (after 3 mg/kg). Conclusions: In rats, liver dysfunction reduced METH clearance, increased brain METH concentrations, and enhanced METH effects on locomotor activity in a dose dependent manner. In addition, this model could be further developed to simulate the associated hepatic dysfunction of key METH abuse comorbidities for preclinical testing of novel pharmacotherapies for effectiveness and/or toxicity in vulnerable populations.
|
url |
https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30471 |
work_keys_str_mv |
AT michaeldhambuchen effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats AT michaeldberquist effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats AT christymsimecka effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats AT mitchellrmcgill effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats AT melindaggunnell effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats AT howardphendrickson effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats AT smichaelowens effectofbileductligationinducedliverdysfunctiononmethamphetaminepharmacokineticsandlocomotoractivityinrats |
_version_ |
1724548079923757056 |